Procalcitonin levels in Sjögren syndrome
Biochimica Clinica, cilt.43, sa.3, 2019 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 43 Sayı: 3
- Basım Tarihi: 2019
- Doi Numarası: 10.19186/bc_2019.020
- Dergi Adı: Biochimica Clinica
- Derginin Tarandığı İndeksler: Scopus
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: procalcitonin (PCT) is a polypeptide secreted as a response a bacterial stimulus. PCT serum concentrations are increased also in some autoimmune diseases. At the best of our knowledge, there is no study in literature that evaluated PCT values in patients with primary Sjögren’s syndrome (pSS). The aim of this paper is to measure PCT values in pSS and to determine if these are related to the disease activity. Methods: this is a case-control study. Two groups of subjects were included: 48 patients with pSS, who met American College of Rheumatology 2012 Classification Criteria for Sjögren's syndrome and 53 healthy subjects as control group (without any acute or chronic disease). The subjects with possible infectious disease were excluded on the basis of their clinical evaluation and laboratory data. Serum PCT values were measured by electrochemiluminometric method. PCT values have been compared between the groups; the correlation between disease activity, measured by Sjögren’s syndrome disease activity index (SSDAI) and PCT levels was evaluated. Results: PCT values in pSS group were within the reference range, but significantly higher than those measured in the control group [median (interquartile range) values were 0.036 ng/mL (0.031-0.044) and 0.020 ng/mL (0.020-0.020) respectively], (p<0.001). No correlation was found between disease activity and PCT values (p=0.63). Conclusions: on the basis of the presented results, PCT could be a candidate marker for differentiating disease activity from the presence of an infection in pSS patients. Future studies in pSS patients with infectious diseases could possibly demonstrate the role of PCT in this context.